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1. INTRODUCTION 
 
Oral delivery of drugs is by far the most preferred route of drug delivery due 
to ease of administration, patient compliance and flexibility in formulation. The 
design of oral controlled drug delivery systems (DDS) is primarily aimed to achieve 
more predictable and increased bioavailability. Gastric emptying time in humans, 
which is normally 2-3 hours through the main absorption area (stomach or upper part 
of intestine), can result in incomplete drug release from DDS leading to diminished 
efficacy of administered dose. Floating Drug Delivery Systems (FDDS) have a bulk 
density is lower than gastric fluids and thus remain buoyant in stomach for a 
prolonged period of time, without affecting the gastric emptying rate. While the 
system is floating on gastric contents, drug is released slowly at a desired rate from 
the system. After the release of drug, the residual system is emptied from the stomach. 
This result is increase in GRT and a better control of fluctuations in plasma drug 
concentrations. Floating systems can be classified into two types, non-effervescent 
system and effervescent systems. Longer residence time in stomach could be 
advantageous for local action in the upper part of small intestine, for example 
treatment of peptic ulcer disease. Ciprofloxacin hydrochloride is a broad-spectrum 
antibiotic active against both Gram-positive and Gram negative bacteria. The dosage 
is equivalent of 250 to 750 mg of ciprofloxacin twice daily (116 mg of ciprofloxacin 
hydrochloride is approximately equivalent to 100 mg of ciprofloxacin). The aim of 
the present study is to formulation and evaluation of floating tablets of ciprofloxacin 
hydrochloride using HPMC (K100M, K4M and E50) in different ratio with sodium 
bicarbonate, magnesium stearate and talc by direct compression techniques1. 
 
FLOATING DRUG DELIVERY SYSTEM 
 
Floating drug delivery system is also known as hydrodynamically balanced 
system (HBS). While the system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system. After release of drug the residual 
system is emptied from the stomach. This results in an increased GRT and a better 
control of the fluctuations in plasma drug concentration2. 
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Advantages of FDDS3: 
 
Floating dosage systems form important technological drug delivery systems 
with gastric retentive behavior and offer several advantages in drug delivery. These 
advantages include: 
  
1. Improved drug absorption, because of increased GRT and more time spent 
by the dosage form at its absorption site. 
2. Controlled delivery of drugs. 
3. Delivery of drugs for local action in the stomach. 
4. Minimizing the mucosal irritation due to drugs, by drug releasing slowly at 
controlled rate. 
5. Treatment of gastrointestinal disorders such as gastro-esophageal reflux. 
6. Simple and conventional equipment for manufacture. 
7. Ease of administration and better patient compliance. 
8. Site-specific drug delivery. 
 
Limitations of FDDS4: 
 
1. Gastric retention is influenced by many factors such as gastric motility, pH 
and presence of food. These factors are never constant and hence the 
buoyancy cannot be predicted. 
2. Drugs that cause irritation and lesion to gastric mucosa are not suitable to 
be formulated as floating drug delivery systems. 
3. High variability in gastric emptying time due to its all or non-emptying 
process. 
4. Gastric emptying of floating forms in supine subjects may occur at random 
and becomes highly dependent on the diameter and size. Therefore 
patients should not be dosed with floating forms just before going to bed. 
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Factors affecting the floating time5,6: 
 
a. Density: Floating is a function of dosage form buoyancy that is dependent on 
the density. Density of the dosage form should be less than the gastric contents 
(1.004gm/ml). 
b. Shape of dosage form: Dosage form unit with a diameter of more than 7.5 mm 
are reported to have an increased GRT competed to with those with a diameter 
of 9.9 mm. Tetrahedron and ring shaped devices with flexural modules of 48 
and 22.5 kilo pounds per square inch are reported to have better floating, 90% 
to 100% retention at 24 hours compared with other shapes. 
c. Concomitant drug administration: Anticholinergics like atropine and 
propantheline, opiates like codeine and prokinetic agents like metoclopramide 
and cisapride; can affect floating time. 
d. Fed or unfed state: Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complex 
(mmc) that occurs in every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach and, if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and 
GRT is considerably longer. 
e. Nature of meal: Feeding of indigestible polymers or fatty acid salts can change 
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release. 
f. Caloric content and feeding frequency: Floating can be increased by four to 10 
hours with a meal that is high in proteins and fats. The floating can increase by 
over 400 minutes when successive meals are given compared with a single 
meal due to the low frequency of mmc. 
g. Age: Elderly people, especially those over 70, have a significantly longer; 
floating. Disease condition such as diabetes and crohn’s disease etc also affect 
drug delivery. 
h. Gender: Mean ambulatory GRT in males (3.4 0.6 hours) is less compared with 
their age and race-matched female counter parts (4.6 1.2 hours), regardless of 
the weight, height and body surface. 
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i. Posture: Floating can vary between supine and upright ambulatory states of 
the patient. 
 
Approaches to design floating drug delivery system: 
Practical approaches in designing FDDS: 
 
The concept of FDDS was first described in the literature as early as 1968, 
when Davis (1968) disclosed a method to overcome the difficulty experienced by 
some persons of gagging or choking after swallowing medicinal pills. The author 
suggested that such difficulty could be overcome by providing pill having a density of 
less than 1.0g/cm3, so that pill will float on water surface. Since then several 
approaches have been used to develop an ideal floating drug delivery system6. 
 
Approaches to design single and multiple unit dosage form7,8: 
 
The following approaches have been used for the design of floating dosage 
forms of single and multiple unit systems. 
 
A. Single unit dosage form 
 
In low density approaches, the globular shells apparently having lower density 
than that of gastric fluid can be used as a carrier like popcorn, poprice, polystrol for 
the drug for its controlled release. The polymer of choice can be either Ethyl cellulose 
or HPMC depending on type of release desired. Finally the product floats on the 
gastric fluid while releasing the drug gradually over a prolonged duration. Fluid filled 
floating chamber type of dosage forms includes incorporation of a gas filled floatation 
chamber in to a micro porous component that houses as a reservoir having apertures 
present at top and bottom walls through which the gastrointestinal tract fluid enters to 
dissolve the drug. Hydro dynamically balanced systems are designed to prolong the 
stay of the dosage forms in the gastric intestinal tract and aid in enhancing the 
absorption. Drugs having a better solubility in acidic environment and also having 
specific site of absorption in the upper part of small intestine is achieved by these 
HBS systems. To retain in stomach for a prolonged period of time the dosage form 
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must have bulk density of less than ‘1’ and has to maintain its structural integrity and 
release drug constantly from the dosage form. Among all the advantages single-unit 
formulations are associated with some limitations/problems such as sticking together 
or being obstructed in the GIT which may lead to potential danger of producing 
irritation. 
 
B. Multiple unit dosage form 
 
Multiparticulate dosage forms are gaining much favor over single-unit dosage 
forms. The potential benefits include increased bioavailability; predictable, 
reproducible and generally short gastric residence time, no risk of dose dumping; 
reduced risk of local irritation, and the flexibility to blend pellets with different 
compositions or release patterns. Because of their smaller particle size these systems 
are capable of passing through the GI tract easily, leading to less inter- and intra-
subject variability. However, potential drug loading of a multiparticulate system is 
lower because of the proportionally higher need for excipients (e.g., sugar cores). 
Most multiparticulate pulsatile delivery systems are reservoir devices coated with a 
reputable polymeric layer. Upon water ingress, drug is released from the core after 
rupturing of the surrounding polymer layer, due to pressure build-up within the 
system. The pressure necessary to rupture the coating can be achieved with swelling 
agents, gas producing effervescent excipients or increased osmotic pressure. Water 
permeation and mechanical resistance of the outer membrane are major factors 
affecting the lag time. Water soluble drugs are mainly released by diffusion; while for 
water insoluble drug, the release is dependent on dissolution of drug. 
 
Types of floating drug delivery system9,10: 
 
Floating drug delivery systems can be divided in to non-effervescent and gas-
generating system. 
 
Non-effervescent systems: This type of system, after swallowing, swells 
unrestrained via imbibition of gastric fluid to an extent that it prevents their exit from 
the stomach. One of the formulation methods of such dosage forms involves the 
Chapter 1                                                                                Introduction  
 
Dept.of Pharmaceutics                       6          J.K.K.Nataraja College of  Pharmacy 
 
mixing of the drug with a gel, which swells in contact with gastric fluid after oral 
administration and maintains a relative integrity of shape and a bulk density of less 
than one within the outer gelatinous barrier. The air trapped by the swollen polymer 
confers buoyancy to these dosage forms. Excipients used most commonly in these 
systems include hydroxypropyl methyl cellulose (HPMC), polyacrylate polymers, 
polyvinyl acetate, Carbopol, agar, sodium alginate, calcium chloride, polyethylene 
oxide and polycarbonates. This system can be further divided into four sub-types: 
a) Colloidal gel barrier system such a system contains drug with gel-forming 
hydrocolloids meant to remain buoyant on the stomach content. This prolongs 
GRT and maximizes the amount of drug that reaches its absorption sites in the 
solution form for ready absorption. This system incorporates high level of one 
or more gel-forming highly soluble cellulose type hydrocolloid, e.g. 
hydroxypropyl cellulose, hydoxy ethyl cellulose, hydroxypropyl methyl 
cellulose (HPMC), polysaccharides and matrixforming polymer such as 
polycarbophil, polyacrylateand polystyrene. On coming in contact with gastric 
fluid, the hydrocolloid in the system hydrates and forms a colloid gel barrier 
around its surface. 
b) Microporous compartment system, this technology is based on the 
encapsulation of a drug reservoir inside a microporous compartment with 
pores along its top and bottom walls. The peripheral walls of the drug 
reservoir compartment are completely sealed to prevent any direct contact of 
gastric surface with the undissolved drug. In the stomach, the floatation 
chamber containing entrapped air causes the delivery system to float over the 
gastric content. Gastric fluid enters through the aperture, dissolves the drug 
and carries the dissolved drug for continuous transport across the intestine for 
absorption. 
c) Alginate beads, in which Multi-unit floating dosage forms have been 
developed from freeze dried calcium alginate. Spherical beads of 
approximately 2.5 mm in diameter can be prepared by dropping sodium 
alginate solution into aqueous solution of calcium chloride, causing the 
precipitation of calcium alginate. The beads are then separated, snap-frozen in 
liquid nitrogen, and freeze-dried at -40 ºC for 24 hours, leading to the 
formation of a porous system, which can maintain a floating force for over 12 
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hours. These floating beads gave a prolonged residence time which is more 
than 5.5 hours. 
d) Raft forming systems have received much attention for the delivery of 
antacids and drug delivery for gastrointestinal infections and disorders. The 
mechanism involved in the raft formation includes the formation of viscous 
cohesive gel in contact with gastric fluids, wherein each portion of the liquid 
swells forming a continuous layer called a raft. This raft floats on gastric fluids 
because of low bulk density created by the formation of CO2. Usually, the 
system contains a gel forming agent and alkaline bicarbonates or carbonates 
responsible for the formation of CO2 to make the system less dense and float 
on the gastric fluids, described an antacid raft forming floating system. The 
system contains a gel forming agent (e.g. alginic acid), sodium bicarbonate 
and acid neutralizer, which forms a foaming sodium alginate gel (raft) when in 
contact with gastric fluids. The raft thus formed floats on the gastric fluids and 
prevents the reflux of the gastric contents (i.e. gastric acid) into the esophagus 
by acting as a barrier between the stomach and esophagus. 
 
Gas-generating (effervescent) systems: These buoyant systems utilize matrices 
prepared with swellable polymers such as methocel, polysaccharides (e.g.chitosan), 
effervescent components (e.g., sodium bicarbonate, citric acid or tartaric acid). The 
system is so prepared that upon arrival in the stomach; carbon dioxide is released, 
causing the formulation to float in the stomach. Other approaches and materials that 
have been reported are a mixture of sodium alginate and sodium bicarbonate, multiple 
unit floating pills that generate carbon dioxide when ingested, floating mini capsules 
with a core of sodium bicarbonate, lactose and polyvinyl pyrrolidone coated with 
hydroxypropyl methylcellulose (HPMC), and floating systems based on ion exchange 
resin technology. 
 
Hollow microspheres / Microballons loaded with drug in their outer polymer 
shelf were prepared by a novel emulsion solvent diffusion method. The 
ethanol/dichloromethane solution of the drug and an enteric acrylic polymer was 
poured into an agitated solution of Poly Vinyl Alcohol (PVA) that was thermally 
controlled at 40ºC. The gas phase is generated in the dispersed polymer droplet by the 
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evaporation of dichloromethane formed and internal cavity in the microsphere of the 
polymer with drug. The microballoon floated continuously over the surface of an 
acidic dissolution media containing surfactant for more than 12 hours10. 
 
Bacterial infections 
Ciprofloxacin hydrochloride is an antibiotic used to treat a number of bacterial 
infections. This includes bone and joint infections, intra abdominal infections, certain 
type of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, 
and urinary tract infections, among others. 
A fluoroquinolone antibiotic used to treat urinary infections and, as eye drops, 
for the treatment ofcorneal ulcers. The drug acts by binding to the enzyme gyrase. Mu
tations lead to an alteration in the structure of thisenzyme leading to antibiotic resistan
ce. Current research suggests the possibility of preventing this process. The drug is on 
the WHO official list. Brand names are Cifran and Cipfil11,12. 
 
Classification of quinolone antibiotics 
Classification Agents Antimicrobial Spectrum General clinical 
indications* 
First 
generation 
Nalidixic acid 
(NegGram) 
Gram-negative organisms 
(but not Pseudomonas 
species) 
Uncomplicated 
urinary tract 
infections 
Cinoxacin 
(Cinobac) 
Second 
generation 
Norfloxacin 
(Noroxin) 
Gram-negative organisms 
(including Pseudomonas 
species), some gram-positive 
organisms 
(includingStaphylococcus 
aureusbut not Streptococcus 
pneumoniae) and some 
Uncomplicated 
and complicated 
urinary tract 
infections and 
pyelonephritis, 
sexually 
transmitted 
Lomefloxacin 
(Maxaquin) 
Enoxacin 
(Penetrex) 
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Classification Agents Antimicrobial Spectrum General clinical 
indications* 
Ofloxacin 
(Floxin) 
atypical pathogens diseases, 
prostatitis, skin 
and soft tissue 
infections Ciprofloxacin 
(Cipro) 
Third 
generation 
Levofloxacin 
(Levaquin) 
Same as for second-
generation agents plus 
expanded gram-positive 
coverage (penicillin-
sensitive and penicillin-
resistant S. pneumoniae) and 
expanded activity against 
atypical pathogens 
Acute 
exacerbations of 
chronic bronchitis, 
community-
acquired 
pneumonia 
Sparfloxacin 
(Zagam) 
Gatifloxacin 
(Tequin) 
Moxifloxacin 
(Avelox) 
Fourth 
generation 
Trovafloxacin 
(Trovan) 
Same as for third-generation 
agents plus broad anaerobic 
coverage 
Same as for first-, 
second- and third-
generation agents 
(excluding 
complicated 
urinary tract 
infections and 
pyelonephritis) 
plus intra- 
abdominal 
infections, 
nosocomial 
pneumonia, pelvic 
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Classification Agents Antimicrobial Spectrum General clinical 
indications* 
infections 
 
Indications for quinolone antibiotics labeled by the U.S. food and drug 
administration 
INDICATIONS AGENTS 
Uncomplicated urinary 
tract infections 
Nalidixic acid (NegGram), cinoxacin (Cinobac), 
norfloxacin (Noroxin), lomefloxacin (Maxaquin), 
enoxacin (Penetrex), ofloxacin (Floxin), ciprofloxacin 
(Cipro), levofloxacin (Levaquin), gatifloxacin (Tequin), 
trovafloxacin (Trovan) 
Complicated urinary tract 
infections and 
pyelonephritis 
Norfloxacin, lomefloxacin, enoxacin, ofloxacin, 
ciprofloxacin, levofloxacin, gatifloxacin 
Lower respiratory tract 
infections (limited) 
Lomefloxacin, ofloxacin, ciprofloxacin, trovafloxacin 
Skin and skin-structure 
infections 
Ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin 
Urethral and cervical 
gonococcal infections 
Norfloxacin, enoxacin, ofloxacin, ciprofloxacin, 
gatifloxacin, trovafloxacin 
Urethral and cervical 
chlamydial and 
gonnococcal infections 
Ofloxacin, trovafloxacin 
Bone and joint infections, 
gram-negative bacterial 
infections 
Ciprofloxacin 
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INDICATIONS AGENTS 
Infectious diarrhea Ciprofloxacin 
Typhoid fever Ciprofloxacin 
Prostatitis Norfloxacin, ofloxacin, trovafloxacin 
Acute sinusitis Ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin 
(Avelox), trovafloxacin 
Acute exacerbations of 
chronic bronchitis 
Levofloxacin, sparfloxacin (Zagam), gatifloxacin, 
moxifloxacin, trovafloxacin 
Community-acquired 
pneumonia 
Levofloxacin, sparfloxacin, gatifloxacin, Moxifloxacin, 
trovafloxacin 
Intra-abdominal 
infections 
Trovafloxacin 
Gynecologic and pelvic 
infections 
Trovafloxacin 
Nosocomial pneumonia Trovafloxacin 
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2. LITERATURE   REVIEW 
 
P. G. Yeole et al., presented a review article about floating drug delivery 
systems, need and development for achieving a prolonged and predictable drug 
delivery profile in the gastrointestinal tract to control the gastric residence time, using 
gastro retentive dosage forms that will provide us with new and important therapeutic 
option13. 
  Shwetha A et al., made a reviewed on floating drug delivery systems with 
special focus on the principle mechanism of flotation to achieve gastric retention, 
including the physiological and formulation variables affecting gastric retention, 
approaches to design single – unit and multiple unit floating systems and their 
classification, summarized the in vitro techniques and in vivo studies to evaluate the 
performance and application of floating system and concluded that prolonging gastric 
retention of dosage form extends the time for drug  absorption. Floating drug delivery 
system promises to be a potential approach for gastric retention14. 
   Patel V. F et al., studied about formulation and evaluation of ciprofloxacin 
tablets and optimized the formulation for type of filler, different viscosity grades of 
HPMC and its concentration. The study revealed that type of filler adds significant 
effect on release of drug from hydrophilic matrix tablet and floating properties. It 
concluded that the different viscosity grades of HPMC had a major influence on drug 
release from hydrophilic matrices as well as on floating properties15. 
M.P.Venkatarajua et al., developed a controlled delivery system for 
propranolol hydrochloride (PPHCL) using the synergistic activity of locust bean gum 
(LBG) and xanthan gum (X). Granules of PPHCL were prepared by using different 
drug: gum ratios of X, LBG alone and a mixture of XLBG (X and LBG in 1: 1 
ratios)16. 
Parikh bhavik anjankumar et al., prepared a floating drug delivery system of 
atenolol in order to increase the gastric residence time (GRT) and comparison of 
natural and synthetic polymer for better sustained effect. The tablets were prepared by 
direct compression. The pre and post compression studies were performed by using IP 
standard formula and procedure17. 
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Mahesh chavanpatil et al., developed ofloxacin sustained release (SR) 
gastroretentive dosage forms (GRDF) for once daily. The design of the delivery 
system was based on the sustained release formulation, with floating and swelling 
features in order to prolong the gastric retention time of the drug delivery systems18. 
Manoj et al., prepared a floating drug delivery system of diltiazem 
hydrochloride using polymers such as hydroxypropyl methylcellulose K100M CR and 
compritol 888 ATO, alone and in combination. The effect of sodium bicarbonate and 
succinic acid on drug release was investigated. The high level of both methocel 
K100M CR and compritol 888 ATO favours the preparation of floating controlled 
release of diltiazem tablets19. 
Inez Jimenez et al., developed a sustained delivery of captopril from floating 
matrix tablets. The study was done using metolose SH4000 sodium bicarbonate and at 
two different compaction pressures. The observation showed that the matrices 
compacted at lower pressure (55MPa) floated in the dissolution medium for more than 
8hr while those compacted at (165MPa) floated only when sodium bicarbonate is 
included in the formulation20. 
Nur and zhanj et al., prepared captopril floating and bioadhesive tablets using 
two grade of HPMC (400 and l5000cps) and carbopol 934P. In vitro dissolution was 
carried out in simulated gastric fluid (enzyme free) at 37 ± 0.1°C using the USP type 
II method. Compared to conventional tablets, release of captopril from these floating 
tablets was apparently prolonged (24hrs). Tablet hardness was found to be a 
determining factor with regard to the buoyancy of the tablets21. 
Chen and hao et al., studied the in vitro performance of floating sustained 
release capsule of verapamil. Capsules filled with mixture of verapamil, HPC and 
effervescent materials are proposed to provide floating and sustained release for over 
10 hrs. The effects of weight filled in the capsule, amount of HPC and the addition of 
effervescent material on the dissolution kinetics were studied22. 
Desai and bolton et al., developed controlled release floating tablets of the 
theophylline using agar and light mineral oil. Tablets were made by dispersing drug 
and mineral oil mixture in a warm agar solution. The resultant mixture was poured 
into tablets moulds, which on cooling and air-drying formed floated CR tablets23. 
Hilton and deasy et al., fabricated an oral sustain release floating tablets of 
amoxicillin trihydrate using various hydrophilic polymers like hydroxy Propyl 
cellulose, sodium alginate, sodium carboxymethylcellulose, HPMC and 
 Chapter 2                                                                      Literature Review  
 
Dept.of Pharmaceutics                       14           J.K.K.Nataraja College of  Pharmacy 
 
methylcellulose. The report revealed that the intrinsic dissolution studies at 𝑃𝐻  2 
showed a decreased drug residence time24. 
Park et al., developed and evaluated floating beads from sodium alginate 
solution containing CaCO3 or NaHCO3 as gas forming agents with riboflavin as a 
model drug.  In vitro release studies revealed that CaCO3 is superior to NaHCO3 as 
gas forming agent in alginate bead preparations, with enhanced buoyancy and 
sustained release properties making them excellent for floating drug delivery 
system25. 
Patil UK et al., developed amlodipine besylate effervescent floating tablets in 
ten different formulations (F1 to F10) by employing different grades of polymers and 
effervescent agents such as sodium bicarbonate and citric acid. The formulations were 
evaluated for various physical parameters, buoyancy studies, dissolution parameters 
and drug released mechanisms. 
Baumgartner S et al., developed floating matrix tablets containing hydroxyl 
propyl methyl cellulose, which after oral administration are designed to prolong the 
gastric residence time, increased the bioavailability and diminished the side effects of 
irritating drugs. The importance of the composition optimization, the formulation 
effects and characterization of the tablets were examined. 
Jimenez-casttellanos et al., designed and tested the invitro floating and 
bioadhesive property of sotalol for oral application. Tablets were prepared by mixing 
the active ingredient with sodium carboxy methyl cellulose, hydroxy propyl cellulose 
and sodium bicarbonate to generate gas. 
Basak, S.C et al., have reviewed about development and in vitro evaluation of 
an oral floating matrix tablet formulation of ciprofloxacin which better absorbed in 
stomach and upper small intestine was formulated as floating matrix tablet using gas 
generating agent (sodium bicarbonate) and hydrophilic polymer 
(hydroxypropylmethyl cellulose) and concluded that invitro drug release study of 
these tablet indicated controlled sustained release for ciprofloxacin and 80-89% 
release at the end of 8 hrs. 
K. Muthusami et al., prepared and evaluated of lansoprazole floating 
micropellets using HPMC, methyl cellulose and chitosan as a carrier and he 
concluded that drug loaded micropellets were found to float on stimulated gastric 
fluid and simulated intestinal fluid for more than 12 hrs. 
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  Brijesh S.Dave et al., have reviewed about gastro retentive drug delivery 
system of ranitidine hydrochloride formulation and invitro evaluation. The result is of 
the full factorial design indicated that the addition of stearic acid reduces the drug 
dissolution due to it’s hydrophobicity and shows sustained release of ranitidine 
hydrochloride from a gastroretentive formulation. A theoretical dissolution profile 
was generated using pharmacokinetic parameters of ranitidine hydrochloride and 
concluded that addition of gel forming polymer HPMC K4M and gas generating agent 
sodium bicarbonate was essential to achieve in vitro buoyancy. 
  Jaimini,M et al., studied about formulation and evaluation of famotidine 
floating tablets by using different grades of methocel K100 and methocel K 15M by 
effervescent technique and showing good in vitro buoyancy. 
Honglei jian et al., developed a controlled release tablets of theophylline using 
sustained release materials such as galactomannan (G) from gleditsia sinensis lam and 
xanthan gum (X), were mixed indifferent ratios of 7: 3, 5:5, and 3:7 to yield enhanced 
release-controlling performance. The polysaccharides content of tablets was 10% 
(w/w), either alone or in mixtures. 
T.Akelesh et al., developed a gastro-retentive floating tablet of Acyclovir by 
direct compression method. The results of in vitro release studies showed that 
optimized formulation F7 could sustain drug release (99.08%) for 16 hr and remain 
buoyant for 24 hrs. Optimized formulation F7 contained 60% of locust bean gum and 
40% sodium alginate out of total floating polymer while amount of xanthan gum is 
same in all 7 batches. 
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3. AIM AND OBJECTIVE 
 
 The aim of the present work is to formulate and evaluate floating tablet of 
ciprofloxacin hydrochloride using natural polymers like xanthan gum and guar 
gum. 
 
 Ciprofloxacin hydrochloride is a second generation fluroquinolone antibiotic. 
It inhibits the replication of DNA interfering with the action of DNA gyrase. It 
is weakly acidic drug and half life of 4 hours. 
 
 According to BCS classification, ciprofloxacin hydrochloride coming under 
class4 category which has low solubility and low permeability. 
 
 Ciprofloxacin is a FDA approved oral antibiotic drug, which has rapid and 
complete absorption after oral administration. 
 
 Gastro –retentive delivery is one of the site specific delivery for the delivery 
of drug either at stomach or intestine. 
 
 As ciprofloxacin hydrochloride has higher absorption site in the upper 
gastrointestinal tract and poor absorption in colon, suggest it is an ideal 
candidate for a gastroretentive drug-delivery system that will prolong the 
gastric residence time of the dosage form, giving prolonged drug release in the 
upper gastrointestinal tract, where absorption of ciprofloxacin hydrochloride is 
well confined. 
 
 A systemic approach for design and development of gastroretensive drug 
delivery system of ciprofloxacin using polymers which increases the gastric 
residence time, decreases the diffusion distance and allow more of the 
antibiotic to penetrate through the gastric mucus layer and act locally at the 
infectious site to enhance the bioavailability and therapeautic efficacy of the 
drug. 
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 Naturally occurring polymers is preferred for controlled formulation because 
of its low cost, naturally available, biocompatible and better patient tolerance 
as well as public acceptance. 
 
 So planned to formulate and evaluate floating tablets of ciprofloxacin 
hydrochloride using natural polymers. 
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4. PLAN OF WORK 
 
The proposed work was carried out to formulate and evaluate floating tablets 
of ciprofloxacin hydrochloride in the following phases: 
 
Phase-I: 
 
 Pre-formulation study of ciprofloxacin hydrochloride 
 Drug excipient compatibility study of ciprofloxacin hydrochloride by 
fourier transform infrared spectroscopy (FT-IR) 
 Preparation of standard curve of ciprofloxacin hydrochloride in 0.1 N 
hydrochloric acid 
 
Phase-II: 
 Pre compression parameters 
 Formulation of floating tablets of ciprofloxacin hydrochloride. 
 Post compression parameters 
 Weight variation 
 Thickness 
 Friability Test 
 Hardness 
 Drug content 
 Tablet density 
 Floating test 
 Swelling study 
 In-vitro dissolution studies 
 Kinetics of drug release 
 
Phase-III: 
Accelerated stability study of the optimized formulation as per  ICH 
Guidelines. 
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5. THEORETICAL BACKGROUND PROFILES 
 
DRUG PROFILE: Ciprofloxacin hydrochloride26 
 
CHEMICAL STRUCTURE: 
                
                   
  
CHEMICAL NAME: 
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1, 4-dihydroquinoline-3-
carboxylic acid hydrochloride. 
 
Molecular formula : C17H18FN3O3.HCL 
 
Molecular weight : 331.346 g/mol 
 
Category  : Ciprofloxacin is a broad spectum fluoroquinolone antibiotics. 
 
Description  : A pale yellow, crystalline powder 
 
Solubility: 
 Ciprofloxacin hydrochloride is soluble in water, and slightly soluble in organic 
solvent.           
 
Storage: 
Store below 40˚C, preferably between 15˚C and 30˚C in a well-closed 
container, when otherwise specified by manufacture. 
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Clinical pharmacology26: 
Mechanism of action 
It is a broad-spectrum antibiotic of the fluoroquinolone class. It is active 
against both Gram-positive and Gram-negative bacteria. It functions by inhibiting 
DNA gyrase, and a type II topoisomerase, topoisomerase IV, necessary to separate 
bacterial DNA, thereby inhibiting cell division 
 
Pharmacodynamics27: 
The mean serum concentration of ciprofloxacin hydrochloride peaked 
approximately 1 h after the oral dose (0.94 mg/l). ... About 27% of the oral dose was 
excreted in urine, whereas the urinary recovery of the i.v. dose was 46%. The absolute 
bioavailability of ciprofloxacin hydrochloride was found to be approximately 60%. 
 
Pharmacokinetics28: 
Absorption 
 The absorption of ciprofloxacin from different regions of the human 
gastrointestinal tract was investigated in four healthy males using a remote-controlled 
drug delivery device (hf-capsule). Significant differences in AUC were observed in 
the control study (oral administration of ciprofloxacin solution without the hf-capsule 
= 100%) and after release of ciprofloxacin in the jejunum (geometric mean: 37%), the 
ileum (mean: 23%), the ascending colon (mean: 7%) and the descending colon (mean: 
5%), whereas Tmax showed no difference for any of the absorption sites. Ciprofloxacin 
release in the stomach resulted in the greatest AUC (mean: 140%). Thus, it is 
concluded that the main absorption site of ciprofloxacin is the upper gastrointestinal 
tract, up to the jejunum. Differences in presystemic metabolism of known drug 
metabolites along the gut could be excluded, as the pattern of urinary recovery of 
desethylene-, sulpho-, and oxo-ciprofloxacin and the parent compound was similar for 
all drug release sites.  
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Distribution: 
 The binding of ciprofloxacin hydrochloride to serum proteins is 20 to 40% 
which is not likely to be high enough to cause significant protein binding interactions 
with other drugs. After oral administration, ciprofloxacin hydrochloride is widely 
distributed throughout the body. Tissue concentrations often exceed serum 
concentrations in both men and women, particularly in genital tissue including the 
prostate. Ciprofloxacin is present in active form in the saliva, nasal and bronchial 
secretions, mucosa of the sinuses, sputum, skin blister fluid, lymph, peritoneal fluid, 
bile, and prostatic secretions. Ciprofloxacin has also been detected in lung, skin, fat, 
muscle, cartilage and bone. The drug diffuses into the cerebrospinal fluid (CSF); 
however, CSF concentrations are generally less than 10% of peak serum 
concentrations. Low levels of the drug have been detected in the aqueous and vitreous 
humors of the eye.  
  
Metabolism: 
The drug is partially metabolized in the liver by modification of the 
piperazinyl group. ... The drug is partially metabolized in the liver by modification of 
the piperazinyl group to at least four metabolites. Ciprofloxacin and its metabolites are 
excreted in urine by both glomerular filtration and by tubular secretion. 
 
Elimination:  
The total renal elimination of the parent compound and its metabolites was 
approximately 60% over the 48-hour collection period in normal renal function and 
was reduced by about 20% in the group with clearances within the range of 10-30 
ml/min. In renal impairment, there was a shift towards a higher proportion of the dose 
being eliminated as M2. M1 contributed only up to 2% of the dose in urine. 
Irrespective of the renal capacity, the amount of M3 recovered in urine was 3-4% 
 
Contraindications: 
 myasthenia gravis 
 caution if QT prolongation 
 caution if congenital long QT syndrome 
 caution if QT prolongation family hx 
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 caution if torsades de pointes hx 
 caution if ventricular arrhythmias 
 
Marketed dosage forms: 
Cifran 250(Sun pharma), Ciprokind 250(Mankind), Cipfil 250(Fourrts) 
 
5.2 POLYMER PROFILE: 
5.2.1 Xanthan gum29: 
Nonproprietary Names 
BP  : Xanthan gum. 
USPNF  :  Xanthan gum 
Synonyms  : Keltrol; Com sugar gum; Rhodigel; Xantural; Polysaccharide B-1459 
 
Empirical formula and molecular weight: 
 
Formula   :  (C35H49O29)n 
Molecular weight  : Approximately 2 X 106 
 
Functional category 
Stabilising agent, suspending agent, viscosity increasing agent. 
 
Applications in pharmaceutical formulation or technology 
Xanthan gum is widely used in oral and topical formulations, cosmetics and 
foods as a suspending agent and stabilising agent. It is also used as a thickening agent 
and emulsifying agent. It is nontoxic, compatible with most other pharmaceutical 
ingredients and has good stability and viscosity properties over a wide PH and 
temperature range. Xanthan gum gels show pseudo plastic behaviour, the shear 
thining being directly proportional to the shear rate. The viscosity returns to normal 
immediately on release of shear stress. 
Recent studies have revealed that xanthan gum can also used as an excipient 
for spray drying and freeze drying processes for better results. 
Although primarily used as a suspending agent, xanthan gum has also been 
used to prepare sustained release matrix tablets. Xanthan gum has been incorporated 
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in an ophthalmic liquid dosage form, which interacts with mucin there by helping in 
prolonged retention of the dosage form in the precorneal area. 
Xanthan gum can be used to increase the bio adhesive strength in vaginal 
formulations and as a binder in colon specific drug delivery systems. Xanthan gum 
also used as a hydrocolloid in the food industry and in cosmetics it has been used a 
thickening agent in shampoos.  
 
Description 
Xanthan gum occurs as a cream or white colored, odourless, free-flowing, fine 
powder. 
 
Typical properties 
Acidity/alkalinity  :  pH =6.0-8.0 for a l%w/v aqueous solution 
Freezing point  :  0°C for al% w/v aqueous solution 
Heat of combustion  :  4.6 j/g (3.5 cal/g) 
Melting point  :  chars at 270°C 
 
Solubility: 
It is practically insoluble in ethanol and ether; soluble in cold or warm water. 
 
Viscosity:  
1200-1600 mPas( 1200-1600 Cp) for a 1% w/v aqueous solution at 25°C. 
 
Specific gravity: 
1.600 at 25°C  
Xanthan gum is a stable material aqueous solutions are stable over a wide PH range (PH 3-12), although they demonstate maximum stability at (PH 4-10) and 
temperatures of 10-60°C. Xanthan gum solutions of less than 1% wlv concentration 
may be adversely affected by higher than ambient temperatures: for example, 
viscosity is reduced. Solutions are also stable in the presence of enzymes, salts, acids 
and bases. 
 
 
Chapter 5                                                                               Drug Profiles   
 
Dept.of Pharmaceutics                       24          J.K.K.Nataraja College of  Pharmacy 
 
Storage conditions: 
The bulk material should be stored in a well-closed container in a cool, dry 
place. 
 
Incompatibilities: 
Xanthan gum is incompatible with oxidising agents, some tablet film coatings, 
carboxy methylcellulose sodium, dried aluminium hydroxide gel and some active 
ingredients such as amitriptyline, tamoxifen and verampil. 
 
Safety: 
Xanthum gum is widely used in oral and topical pharmaceutical 
formulations,cosmetics and food products and is generally regarded as nontoxic and 
nonirritant at the levels empolyed as a pharmaceurtical excipient. The estimated 
acceptable daily intake for xanthan gum has been set by the WHO at up to 10 mg/kg 
body weight. 
 
Related substances: 
Guar gum; ceratonia 
 
5.2.2 GUAR GUM30: 
Nonproprietary names 
BP   :  Guar galactomannan; 
PhEur    :  Guar galactomannanum; 
USPNF  :  Guar gum. 
Synonyms   :  Galactosol; Guar flour; Jaguar gum; Meyprogat;  
Meyprodor; Meyprofin. 
 
Empirical formula and molecular weight 
Formula  : (C଺, CHଵଶ, O଺)n  
Molecular weight :  2,20,000 
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Structural formula 
Guar gum consists of linear chains of (1:4)-13-d-mannopyranosyl units with a-
d-galactopyranosyl units attached by (1:6) linkages. The ratio of d-galactose to d-
mannose is between 1: 1.4 and 1: 2. 
 
Functional category 
Suspending agent, tablet binder, tablet disintegrant, and viscosity increasing 
agent. 
 
Applications in pharmaceutical formulation or technology 
Guar gum used in the preparation of sustained release matrix tablets in the 
place of cellulose derivatives such as methylcellulose. It is used in solid dosage forms 
as a binder and disintegrant, in oral and topical products as a suspending, thickening, 
and stabilizing agent; and also as a controlled release carrier. Guar gum has also been 
examined for use in colonic drug delivery. 
 
Table No.1: Uses of guar gum: 
 
Use Concentration (%) 
Emulsion stabilizer  1  
Thickener for lotions and creams  Up to 2.5  
Tablet binder  Up to 10  
 
Description  
Guar gum obtained from the ground endosperms of Cyamopsis tetragonolobus 
(L.) Taub. (Leguminosae). It consists chiefly of a high-molecular- weight 
hydrocolloidal polysaccharide, composed of galactan and mannan units combined 
through glycoside linkages, which may be described chemically as a galactomannan. 
Guar gum occurs as an odorless or nearly odorless, white to yellowish-white powder 
with a blend taste.  
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Typical properties 
 pH = 5.0—7.0 (1% w/v aqueous dispersion)  
 
Solubility:  
It is practically insoluble in organic solvents. It swells almost immediately to 
form a highly viscous and thixotropic solution in cold or hot water,  
 
Viscosity:  
1.86 Pa s (4860 CP) for 1% w/v dispersion.  
 
Stability and storage conditions27: 
Guar gum powder should be stored in a well closed container in a cool and dry 
place.  
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5.3 EXCIPIENT PROFILE: 𝟓. ૜. ૚ ܁۽۲𝐈܃ۻ ۰𝐈۱ۯ܀۰۽ۼۯ܂۳૜૚: 
Nomenclature 
Non-proprietary names: 
JP    :  Sodium bicarbonate 
BP   :  Sodium bicarbonate 
PhEur   :  Natriihydrogencarbonas 
USP   :  Sodium bicarbonate 
 
Chemical name :  Carbonic acid monosodium salt 
Formula: 
Structural Formula  : NaHCOଷ 
 
Physical and chemical properties: 
Molecular weight : 84.01 
Color : Pale yellow 
Nature  : Crystalline powder 
Odour  : Odourless 
Taste :  Saline/slight alkaline 
Density : 0.869-2.173 g/cm3 
Moisture content  : less than 1 %w/w 
Solubility  : Soluble in water, practically insoluble in 
  ethanol(95%) and ether. 
Osmolarity : 1.39% w/v aqueous solution is iso osmotic with serum. 
Melting point :  270 °C (with decomposition) 
 
Functional category30: 
Alkalizing agent, therapeutic agent 
 
Applications: 
 Used in pharmaceutical formulation as a source of carbon dioxide in 
effervescent tablets and granules. 
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 Used to produce or maintain an alkaline pH in a preparation, like solution of 
erythromycin, lidocaine and niacin etc. 
 Used to produce a sodium salt of the active ingredient that has enhanced 
solubility. 
 Used as a freeze-drying stabilizer and in toothpaste. 
 Used as a gas forming agent in alginate raft system and in floating drug 
delivery system. 
 
Stability and storage: 
Sodium bicarbonate is stable in dry air but slowly decomposed in moist air 
and should therefore be stored in well-closed container in a cool dry place. 
 
Safety: 
Orally ingested sodium bicarbonate neutralizes gastric acid with the evolution 
of carbon dioxide and may cause stomach cramps and flatulence. 
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𝟓. ૜. ૛ ۺۯ۱܂۽܁۳૜૛: 
Nonproprietary names: 
Lactose (BP), Lactose monohydrate (PhEUR, USP-NF). 
 
Synonym: 
CapsuLac, GranuLac, Lactochem, lactosummonohydricum, monohydrate, 
Pharmatose, PrismaLac, SacheLac, SorboLac, pheroLac, SuperTab 3OGR, 
Tablettose. 
 
Chemical name and CAS registry number: 
          O-b-D-Galactopyranosyl-(1 !4)-a-D-glucopyranose monohydrate,[ 10039-26-6] 
 
Emprical formula and molecular weight: 
Formula   :  C12H22O11H2O,  
Molecular weight :  360.31 
 
Description33: 
In solid state, lactose appears as various isomeric forms, depending on the 
crystallization and drying conditions, i.e a lactose monohydrate, 13-lactose 
anhydrous, and a-lactose anhydrous. Lactose occurs as white to off-white crystalline 
particles or powder, it is odorless and slightly sweet-tasting 
 
Structural formula: 
 
 
 
 
 PH  : 5.5-8.9 (1%w/w aqueous solution at 25°) 
Solubility  :  Insoluble in chloroform, ethanol, ether. Soluble in water in  
ratio of 1 in 5.24 
Melting point : 201-202°C (for dehydrated a-lactose monohydrate) 
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Moisture content: 
Lactose monohydrate contains normally had a range of 4.5-5.5% w/w water 
content. 
 
Functional category: 
Dry powder inhaler carrier, lyophilization aid, tablet binder, tablet and capsule 
diluent, tablet and capsule filler. 
 
Applications in pharmaceutical formulation or technology34: 
Lactose is widely used as a filler and diluent in tablets and capsules. Lactose is 
also used as a diluent in dry-powder inhalation. Lactose is added to freeze-dried 
solutions to increase plug size and aid cohesion. Lactose is also used in combination 
with sucrose to prepare sugar-coating solutions. It may also be used in intravenous 
injections. Lactose is also used in the manufacture of dry powder formulations for use 
as aqueous film-coating solutions or suspensions. Direct-compression grades of 
lactose monohydrate are available as spray-dried lactose and anhydrous lactose. 
 
Incompatibilities35: 
A Millard-type condensation reaction is likely to occur between lactose and 
compounds with a primary amine group to form brown, or yellow-brown-colored 
products. Lactose is also incompatible with amino acids, amphetamines and lisinopril. 
 
Stability and storage conditions36: 
Mold growth may occur under humid conditions (80% relative humidity and 
above). Lactose may develop a brown coloration on storage, the reaction being 
accelerated by warm, damp conditions. Solutions show mutarotation. Lactose should 
be stored in a well-closed container in a cool, dry place. 
 
Safety: 
Lactose is widely used as a filler and filler-binder in orals and injections 
Adverse reactions to lactose are largely attributed to lactose intolerance, results in 
lactose being undigested and may lead to cramps, diarrhea, distension, and flatulence. 
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𝟓. ૜. ૜ ۻۯ𝐆ۼ۳܁𝐈܃ۻ ܁܂۳ۯ܀ۯ܂۳૜ૠ,૜ૡ: 
Non proprietary name: 
BP   :  magnesium stearate, 
JP   :  magnesium stearate, 
Pheur   :  magnesiistearas, 
USPNF :  magnesium stearate. 
 
Synonyms: 
Magnesiumocts decanoate; octadecanoicacid, magnesium salt; stearic acid, 
magnesium salt 
 
Chemical name and CAS registry number: 
Octadecanoic acid magnesium salt [557-04-0] 
 
Emperical formula:             Cଷ଺H଻଴ Mg Oସ 
 
Molecular weight:  
591.34 
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Functional category: 
Tablet and capsule lubricant 
 
Application in pharmaceutical formulation or technology: 
Magnesium stearate is widely used in cosmetics, foods and in pharmaceutical 
formulation. It is primarily used as a lubricant in capsule and tablet manufacture. 
 
Description: 
Magnesium stearate is a very fine, light white, precipitated or mild, 
implantable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greesy to touch and readily adheres to the skin. 
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6. MATERIALS AND METHODS 
 
The list of materials and equipments used were illustrated in the table no’s 2&3. 
LIST OF MATERIALS 
Table no.2: Materials and their suppliers 
S.No. MATERIAL SUPPLIED BY 
1. Ciprofloxacin hydrochloride Fourrts  India pvt, Ltd 
2. Xanthan gum Cadila pharma pvt, Ahmedabad 
3. Guar gum Zydus pharma pvt, Hosur 
4. Sodium bicarbonate Medo pharm pvt. Ltd, 
5. Lactose Orchid pharma pvt,ltd 
6. Magnesium stearate Bafna pharma pvt,ltd 
7. Hydrochloric acid Merck specialties pvt,ltd, Mumbai 
8. Methanol Medo pharm pvt,ltd,Chennai 
 
LIST OF INSTRUMENTS 
Table No.3: Equipment and their manufacturer 
 
 
S.No. INSTRUMENTS MANUFACTURER 
1. Electronic balance Shimadzu ELB-300 
2. Sieve no 40 Jaico metals 
3. 
Proton mini press tablet 
punching machine 
Proton 
4. Tablet hardness tester Pfizer hardness tester 
5. Friability test apparatus Roche Friabilator 
6. 
Tablet dissolution 
apparatus 
Lab India Disso 2000 
7. Stability control oven Biotechno lab, BTL 
8. 
UV-Visible 
spectrophotometer 
Lab India,Lambda 25 
9. FTIR spectrophotometer Bruker Alpha 
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6.1 PRE-FORMULATION STUDIES39,40,41: 
Preformulation may be described as a phase of the research and development 
process where the formulation scientist characterizes the physical, chemical and 
mechanical properties of new drug substances, in order to develop stable, safe and 
effective dosage forms.  
        
6.1.1 Organoleptic properties: 
Colour : A small quantity of pure ciprofloxacin hydrochloride powder was taken in a 
butter paper and viewed in well illuminated place. 
Taste and odour : Very less quantity of ciprofloxacin hydrochloride was used to get 
taste with the help of tongue as well as smelled to get the odour. 
 
6.1.2 Solubility analysis42: 
Solubility is important pre-formulation parameter because it affects the 
dissolution of drug bio availability of drug. Solubility of ciprofloxacin hydrochloride 
was determined in methanol, ethanol, dimethyl fluoride, methylchloride, 0.1N 
hydrochloric acid. Solubility studies were performed by taking excess amount of 
ciprofloxacin hydrochloride in different beakers containing the solvent. 
6.1.3 Melting point43: 
       The melting point of ciprofloxacin hydrochloride was determined by capillary 
method, using small quantity of ciprofloxacin hydrochloride was taken and placed in 
apparatus and determined the melting point and matched with standards. 
6.1.4 Loss on drying44:  
Determined on 1 g by drying in an oven at 100°C to 105°C for 3 hours. Mixed 
and accurately weighed the substance to be tested. Tare a glass stopper, shallow 
weighing bottle that has been dried for 30 minutes under the same conditions to be 
employed in the determination. Weighed the empty bottle(W1). Put the sample in 
bottle, replace the cover, and accurately weighed the empty bottle with contents (W2). 
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By gentle, sidewise shaking, distributed the sample as evenly as practicable to a depth 
of about 5 mm. Placed the loaded bottle in the drying chamber. Dried the sample at 
the specified temperature in desicator before weighing. Weighed the bottle(W3). The 
difference between successive weights should not less than 0.3%. 
The loss on drying is calculated by the formula: 
(W2- W3) 
% LOD = ----------------------------- X 100 
(W2-W1) 
 Where, W1 = Weight of empty weighing bottle 
  W2 = Weight of weighing bottle + sample 
  W3 = Weight of weighing bottle + dried sample 
 
6.1.5 Drug powder characterization: 
6.1.5.1 Angle of repose: Angle of repose is the maximum angle of a stable slope 
determined by friction, cohesion and the shapes of the particles. The internal angle 
between the surface of the pile and horizontal surface is known as the angle of repose 
and is related to the density, surface area and co-efficient of friction of the raw 
material45,46. 
Ө = tan-1 (h/r) 
Where, h = height of heap, r = radius of heap, Ө = angle of repose. 
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Table-4: Limits: 
Angle of repose Flow property 
<25o Excellent 
25-30 o Good 
30-40 o Passable 
>40 o Very poor 
 
6.1.5.2 Bulk density: Bulk density is defined as the mass of the powder divided by 
the bulk volume. Bulk density largely depends on particle shape, as the particle 
become more spherical in shape, bulk density was increased. In addition as the 
granule size increases bulk density decreases47. 
A quantity of 5 gm of powder weighed and transferred to a measuring cylinder 
and observed the volume occupied by the sample. The initial volume was calculated. 
Bulk density was calculated using the formula48. 
Bulk density = Bulk mass / Bulk volume 
6.1.5.3 Tapped density: Tapped density is achieved by mechanically tapping a 
measuring cylinder containing a powder sample. After observing the initial volume, 
the cylinder is mechanically tapped and volume readings are taken until little further 
volume changes is observed the mechanical tapping is achieved by raising the 
cylinder and allowing it to drop under its own weigh a specific distance device that 
rotates device during tapping may be preferred to minimize any possible separation of 
the mass during tapping down49,50. 
  The powder in the measuring cylinder were tapped for specific times at a 
height of 2.5 cm at a interval of 2 seconds. The powder in the graduated cylinder were 
tapped for specific times at a height of 2.5 cm at an interval of 2 seconds. The final 
volume occupied by the sample was noted and tapped density was calculated by using 
the formula: 
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Tapped density = 
Vf
m
 
 Where, m = initial weight of material in gm, Vf = volume of material after 
tapping. 
 Generally replicate determinations are desirable for the determination of this 
property. 
6.1.5.4 Measurement of powder compressibility51: 
  Based on the apparent bulk and the tapped density, the percentage 
compressibility of bulk was determined by the following formula.  
Compressibility index: = 
0
0 )(100
V
VfV 
 
Where, Vf = final tapped volume, Vo = initial un tapped volume 
Table-5: Limits: 
S.no Compressibility index Flow 
1 5-12 Free flow 
2 12-16 Good flow 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Verypoor 
6 >40 Extremelypoor 
 
HausnerRatio: = 
Vf
V0
 
Where, Vf = final tapped volume, Vo = initial un tapped volume. 
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Table-6: Limits: 
S.No Hausner’ ratio Flow 
1 1-1.2 Free flowing 
2 1.2-1.6 Cohesive powder 
 
6.2 COMPATIBILITY STUDY: 
Drug excipient compatibility studies by FT-IR52,53: 
IR spectra of drug, polymer and drug and polymers, individual excipients, 
drug and polymers and excipients were obtained using FT-IR 
Drug and excipients were analyzed by IR spectral studies using KBr pellet 
technique. In this method, the drug and KBr were mixed at the ratio of 1:100. Then 
these mixtures were pressed in to a pellet. The FT-IR spectra were recorded using 
KBr pellet method in the region 400-4000 cm-1. Spectra were recorded for pure drug, 
pure excipients, and physical mixture of drug and polymer, drug, polymer and 
excipients. 
6.3 STANDARD CURVE OF CIPROFLOXACIN HYDROCHLORIDE DRUG: 
The calibration curve is based on the spectrophotometry. The maximum 
absorption was observed at 276nm. It obeyed Beer’s law in the concentration range of 
2-10 µg/mL. 
Preparation of stock and standard solution54,55,56: 
            The stock solution was freshly prepared  by dissolving 100mg of ciprofloxacin 
hydrochloride in few ml of methanol (5ml) in a 100ml volumetric flask and then made 
up the solution upto the mark using 0.1N hydrochloric acid for obtaining the solution 
of strength 1000 µg/mL (stock I). 10ml of this solution is diluted to 100ml with 0.1N 
hydrochloric acid to obtain a solution of strength 100 µg/mL (stock II) 
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Preparation of various concentrations57: 
10 ml stock solution was taken from stock solution-2 and volume made up to 
100 ml by using 0.1N hydrochloric acid to get 10 µg/ml concentrations. From this 
solution with draw 2, 4, 6, 8, 10 ml of solution in to the 10 ml volumetric flask and 
volume made up to 10 ml by using 0.1N hydrochloric acid to get the concentrations 2, 
4, 6, 8, 10 µg/ml. 
6.4 Preparation method of ciprofloxacin hydrochloride floating tablets58,59:  
Ciprofloxacin hydrochloride was mixed with the required quantities of polymers 
(xanthan gum and guar gum) sodium bicarbonate (12%), and lactose by geometric 
mixing. The powder blend was then lubricated with magnesium stearate (2%) and 
mixed for about 3 minutes. Finally this mixture was compressed on proton mini press 
tablet punching machine. 
Formulation composition of gastroretentive tablets of ciprofloxacin 
hydrochloride 
Table:7 Quantity of raw materials Per tablet (In mg) 
S. 
NO 
INGREDIE
NTS 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Ciprofloxaci
n HCL 
250 250 250 250 250 250 250 250 250 
2 Xanthan gum 10 10 - 15 15 - 20 20 - 
3 Guar gum 10 - 10 15 - 15 20 - 20 
4 Sodium 
bicarbonate 
20 20 20 20 20 20 20 20 20 
5 Lactose 25 35 35 15 30 30 5 25 25 
6 Magnesium 
stearate 
5 5 5 5 5 5 5 5 5 
7 Total weight 320 320 320 320 320 320 320 320 320 
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6.5 Evaluation of floating tablets of ciprofloxacin hydrochloride60,61: 
  Evaluation was performed to assess the physicochemical properties and 
release characteristics of the developed formulations. 
Following parameters were evaluated 
 Tablet thickness 
 Weight variation test 
 Hardness 
 Friability 
 Content uniformity 
 Buoyancy/floating test 
 Swelling studies 
 In vitro drug release studies 
6.5.1 Tablet thickness: 
  The thickness in millimeters (mm) was measured individually for 10 pre 
weighed tablets by using vernier calipers. The average thickness and standard 
deviation were reported. 
6.5.2 Weight variation: 
 Twenty (20) tablets from each batch were individually weighed in grams (gm) 
on an analytical balance. The average weight and standard deviation were calculated 
and the results were expressed as compliance or non-compliance of set limits. 
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Table: 8: Weight variation tolerance 
Average weight (mg) % Deviation allowed 
80 or less 10 
80-250 7.5 
More than 250 5 
 
6.5.3 Tablet hardness: 
Tablet hardness was measured using a Monsanto hardness tester. The lower 
plunger was placed in contact with the tablet and a zero reading was taken. The 
plunger was then forced against a spring by turning a threaded bolt until the tablet 
fractured.  The crushing strength of the 10 tablets with known weight and thickness of 
each was recorded in kg/cm2 and the average hardness and standard deviation was 
reported. 
6.5.4 Friability62: 
Twenty (20) tablets were selected from each batch and weighed. Each group 
of tablets was rotated at 25 rpm for 4 minutes (100 rotations) in the roche friabilator. 
The tablets were then dusted and re-weighed to determine the loss in weight. 
Friability was then calculated as percent weight loss from the original tablets. 
6.5.5 Content uniformity63,64: 
The formulated ciprofloxacin hydrochloride floating tablets were assayed for 
drug content. From each batch of prepared tablets, ten tablets were collected randomly 
and powdered. a quantity of powder equivalent to weight of one tablet was transferred 
in to a 100 ml volumetric flask, to this 100 ml of methanol was added and then the 
solution was subjected to sonication for about 2 hours. The solution was made up to 
the mark with methanol. The solution was filtered and suitable dilutions were 
prepared with methanol. Same concentration of the standard solution was also 
prepared. The drug content was estimated by recording the absorbance at 276 nm by 
using UV-Visible spectrophotometer. 
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6.5.6 Buoyancy / Floating Test65: 
The in vitro buoyancy was determined by floating lag time. The tablets were 
placed in a 100-ml beaker containing 0.1N hydrochloric acid.  The time required for 
the tablet to rise to the surface and float was determined as floating lag time and total 
duration of time by which dosage form remain buoyant is called Total Floating Time 
(TFT).    
6.5.7 Swelling Index66: 
The swelling behavior of dosage unit can be measured either by studying its 
dimensional changes, weight gain or water uptake. The water uptake study of the 
dosage form was conducted by using USP dissolution apparatus-II in a 900ml of 
distilled water which was maintained at 37o+ 0.5oc, rotated at 50 rpm. At selected 
regular intervals the tablet was withdrawn and weighed. Percentage swelling of the 
tablet was expressed as percentage water uptake (%WU). 
%WU   = (Wt - Wo) * 100 / Wo 
Where Wt is the weight of the swollen tablet and   Wo   is the initial weight of 
the tablet. 
6.5.8 Dissolution study of tablets67,68: 
Apparatus : Dissolution test apparatus -2; USP-32 
Method                         : Paddle method 
Dissolution medium      : 0.1N HCl 
Volume                          : 900 ml 
Temperature                 : 37 + 0.5 C 
Speed                            : 50 rpm 
Procedure 
The tablet was placed inside the dissolution vessel. 5ml of sample were 
withdrawn at time intervals of 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, 8hr, 10hr, 12hr. The 
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volume of dissolution fluid adjusted to 900 ml by replacing 5ml of dissolution 
medium after each sampling. The release studies were conducted with 6 tablets, & the 
mean values were plotted versus time. 
Each sample was analyzed at 276 nm using double beam UV and visible 
spectrophotometer against reagent blank. 
The drug concentration was calculated using standard calibration curve. 
6.6 KINETIC DATA ANALYSIS69,70: 
The analysis of drug release mechanism from a pharmaceutical dosage form is 
an important but complicated process and is practically evident in the case of matrix 
systems. As a model-dependent approach, the dissolution data was fitted to five 
popular release models such as zero-order, first-order, diffusion and exponential 
equations, which have been described in the literature. The order of drug release from 
matrix systems was described by using zero order kinetics or first orders kinetics. The 
mechanism of drug release from matrix systems was studied by using Higuchi 
equation, erosion equation and peppas-Korsemeyer equation. 
6.6.1 Zero order release kinetics71: 
It defines a linear relationship between the fractions of drug released versus time. 
Q = kot 
Where, Q is the fraction of drug released at time t and ko is the zero order 
release rate constant. 
A plot of the fraction of drug released against time will be linear if the release 
obeys zero order release kinetics. 
 6.6.2 First order release kinetics72: 
Wagner assuming that the exposed surface area of a tablet decreased 
exponentially with time during dissolution process suggested that drug release from 
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most of the slow release tablets could be described adequately by apparent first-order 
kinetics. The equation that describes first order kinetics is 
In (1-Q) = - K1t 
Where, Q is the fraction of drug released at time t and k1 is the first order 
release rate constant. 
 Thus, a plot of the logarithm of the fraction of drug remained against time will 
be linear if the release obeys first order release kinetics. 
6.6.3 Higuchi’s equation: 
 
It defines a linear dependence of the active fraction released per unit of surface 
(Q) on the square root of time. 
Q=  𝐊𝟐 𝐭½ 
Where, K2 is the release rate constant. 
A plot of the fraction of drug released against square root of time will be linear 
if the release obeys higuchi equation. This equation describes drug release as a 
diffusion process based on the Fick’s law, square root time dependant. 
 
6.6.4 Korsemeyer equation: 
 
In order to define a model, which would represent a better fit for the 
formulation, dissolution data was further analyzed by peppas and korsmeyer equation 
(power law). 
  𝐌𝐭/𝐌𝛂  = K. 𝐭𝐧 
 
Where, Mt  is the amount of drug released at time t and Mα  is the amount 
released at time α, thus the Mt/Mα  is the fraction of drug released at time t, k is the 
kinetic constant and n is the diffusional exponent. A plot between log of Mt/Mα  
against log time will be linear if the release obeys peppas and korsmeyer equation and 
the slope of this plot represents “n” value. 
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Table-9: Diffusion exponent and solute release mechanism for cylindrical shape 
 
Diffusion Exponent Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0. 89 Anomalous (non-fickian) diffusion 
0.89 Case II transport 
n>0.89 Super case II transport 
 
 
6.7 Stability Studies: 
The optimized formulation was subjected to stability studies as per I.C.H 
guidelines. Samples were kept at 40°c with 75% RH and analyzed for weight 
variation, hardness, friability, drug content and In vitro dissolutions study for every 
month for a period of three months. 
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7. RESULTS AND DISCUSSION 
7.1 PREFORMULATION STUDY 
These tests were performed as per procedure given in 6.2.1. The results were 
illustrated in table no 10. 
 
7.1.1 Organoleptic properties: 
 Table-10: Observation of organoleptic properties: 
TEST SPECIFICATION OBSERVATION 
Colour Pale yellow Pale yellow 
Odour 
 
Odour less 
 
Odourless 
 
Taste  Tasteless Tasteless 
 
7.1.2 Solubility analysis: 
 Ciprofloxacin hydrochloride samples are examined and it was found to be 
soluble in water and slightly soluble methanol, soluble in dimethyl formamide. It also 
dissolves in dilute alkali and in dilute acids. 
7.1.3 Melting point of drug: 
 The melting point of ciprofloxacin hydrochloride was determined by capillary 
method, melting point of ciprofloxacin hydrochloride was found to be 255°C.  
Melting point compared with USP standards that showed that drug is pure. 
7.1.4 Loss on Drying: 
It was determined as per procedure given in 6.2.4. The results was given in 
table no.11 
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Table-11: Observations for loss on drying 
 
Test Loss on drying Observation 
Loss on drying Not more than 0.5% 0.42% 
 
The loss drying of drug was founded as 0.42 which is within the limit. 
 
7.1.5 Drug powder characterization: 
7.1.5.1 Angle of repose: 
It was determined as per procedure given in 6.1.5.1. The results was given in 
table no.12 
 
Table-12: Angle of repose 
 
Material Angle of repose 
Ciprofloxacin hydrochloride 28.11 
 
The results indicating that the raw material has excellent flow property. 
 
7.1.5.2 Flow properties: 
It was determined as per procedure given in 6.2.5.2 to 6.2.5.4. The results was 
given in table no.13 
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Table-13: Flow properties of pure drug 
Material Bulk 
density 
Tapped density Carr’s 
index(%) 
Hausner ratio 
(%) 
Ciprofloxacin 
hydrochloride 
0.23 0.46 11.02 1.134 
 
The results are clearly indicating that the ciprofloxacin hydrochloride raw 
material has good flow property. 
 
7.2  Drug-polymer compatibility study: 
FTIR studies: 
The FTIR spectra of the pure drug, excipient and physical mixture of drug and 
excipient were recorded in between 400-4000 wave number (cm-1). No peaks are 
observed which interfere with the main drug peaks. The following spectrum and table 
shows IR spectrum for drug and polymer and the wave number of characteristic bands 
for the same. 
The IR Spectrum preview pictures are as follows: 
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Fig. No: 1: IR Spectrum of ciprofloxacin hydrochloride standard 
 
 
Fig. No: 2: IR Spectrum of xanthan gum 
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Fig. No: 3: IR Spectrum of guar gum 
 
 
Fig. No: 4: IR Spectrum of magnesium stearate 
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Fig. No: 5: IR Spectrum of lactose 
 
 
Fig. No: 6: IR Spectrum of ciprofloxacin hydrochloride and xanthan gum 
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Fig. No: 7: IR Spectrum of polymers and excipients 
  
Table 14: FT-IR Peaks of various components 
S.No Peak in pure 
drug (cm-1) 
Functional  
Group 
Type of 
vibration 
Peak in 
Physical 
mixture 
1. 3533.35 Amine (N-H) Stretch 
(medium) 
3269.12 
2.  1708.81 Ketone(C=O)     Stretch 
(medium) 
1718.46 
3. 1623.95      Alkene (C=C) Stretch 
(Strong) 
1608.52 
4. 1271.00 Carbonyl(C-O) Stretch 
(Scissoring) 
1276.79 
 
 Compatibility studies were performed using IR spectrophotometer. The IR 
spectrum of pure drug and physical mixture of drug and polymer were studied. 
          From the above results functional groups and type of vibrations are noted 
(Table no:14) In case of FTIR study there was no disappearance or appearance of 
already existing peaks. Hence drugs were found to be compatibles with excipients. 
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7.3 STANDARD CURVE OF CIPROFLOXACIN HYDROCHLORIDE  PURE 
DRUG: 
Calibration curve of ciprofloxacin hydrochloride was determined by plotting 
absorbance (nm) versus concentration (µg/ml) at 276 nm. The results obtained are as 
follows. 
Table -15: Standard curve of ciprofloxacin hydrochloride 
Concentration µg/ml Absorbance 
0 0 
2 0.193 
4 0.421 
6 0.613 
8 0.800 
10 0.985 
 
The linear regression analysis was done on absorbance data points. A straight 
line generated to facilitate the calculation of amount of drug, the equation is as 
follows: 
Y = mx + c 
Where Y=absorbance, m=slope, x=concentration 
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Fig No.8: Standard plot for ciprofloxacin hydrochloride in 0.1 N HCL 
 
7.4 EVALUATION OF FORMULATED METHODS: 
Before formulating floating tablets pre compression parameter were evaluated. 
The following parameters were carried out by the procedure given in 6.1.5. The 
results were illustrated in table no.16 
Table-16: Evaluation of powder characteristics: 
Formulation 
code 
Angle of  
repose 
(degree± SD) 
BD 
(gm/ml± 
SD) 
TD 
(gm/ml± 
SD) 
Carr’s 
index 
(%± SD) 
Hausner 
ratio 
(%± SD) 
F1 26.11±0.02 0.313±0.02 0.364±0.01 14.54±0.03 1.05±0.03 
F2 27.01±0.01 0.324±0.05 0.381±0.02 15.11±0.04 1.06±0.02 
F3 26.02±0.01 0.334±0.04 0.376±0.03 13.59±0.02 1.13±0.03 
F4 25.04±0.02 0.342±0.02 0.384±0.02 16.42±0.04 1.37±0.05 
F5 26.94±0.06 0.294±0.02 0.323±0.04 13.13±0.06 1.12±0.05 
F6 25.32±0.06 0.263±0.01 0.334±0.04 15.23±0.03 1.13±0.04 
F7 26.13±0.03 0.256±0.05 0.374±0.04 14.46±0.06 1.14±0.02 
F8 27.10±0.06 0.305±0.05 0.332±0.03 13.31±0.07 1.14±0.04 
F9 26.36±0.04 0.332±0.02 0.336±0.01 16.21±0.05 1.28±0.04 
y = 0,1x 
R² = 0,9987 
0
0,2
0,4
0,6
0,8
1
1,2
0 2 4 6 8 10 12
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Concentration(μg/ml) 
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             Angle of repose for all formulations were examined .the values were found to 
be with in the range from 25.04±0.02 to 27.10±0.06. This indicates that good flow 
property of powder blend. 
         The bulk density and tapped density values were found to be with in the range 
from 0.256±0.05 to 0.334±0.04 and 0.323±0.04 to 0.381±0.02 respectively.  
         The hausners ratio values were found to be with in the range from 1.05±0.03 to 
1.37±0.05.this indicates that good flow property of powder blend. 
Based on the results the physical mixture was found to be suitable for direct 
compression. So F1 to F9 batches were formulated accordingly to the composition 
given in table 7 of and kept in for evaluation. 
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7.5  EVALUATION OF FORMULATED TABLETS: 
Table-17: Evaluation of formulated tablets 
Formulation 
code 
Weight 
variation 
(n=20) 
(mg ± SD) 
Hardness 
(kg/cm2± 
SD) 
 
Friability 
(%) 
Drug 
content 
(%± SD) 
 
Thickness 
(%± SD) 
F1 319±2.99 4.1±0.34 0.11 96.76±0.19 3.3±0.12 
F2 320±1.98 4.0±0.71 0.23 95.14±0.23 3.2±0.20 
F3 318±3.5 4.1±0.22 0.12 96.87±0.41 3.3±0.03 
F4 320±6.1 4.1±0.32 0.26 97.23±0.22 3.3±0.14 
F5 320±1.3 4.0±0.28 0.22 96.48±0.26 3.3±0.02 
F6 319±6.59 4.1±0.37 0.14 95.67±0.17 3.2±0.53 
F7 318±1.6 4.0±0.09 0.13 94.87±0.32 3.3±0.04 
F8 319±3.06 4.0±0.42 0.25 96.28±0.33 3.2±0.16 
F9 320±3.9 4.0±0.06 0.13 96.87±0.16 3.2±0.29 
 
The formulated floating tablets were then evaluated for various physical 
characteristics like thickness, weight variation, hardness, friability and drug content. 
The weight variation of tablets was uniform in all formulations and ranged from 
318±1.6 to 320±3.9. The % deviation is coming with in 5% to 7% range for this 
accepted % deviation should be 5 % for 320mg tablet. F1-F9 batches come with in 
limit and passed the test. The hardness of the prepared tablets was ranged from 
4.0±0.06 to 4.1±0.37, friability values were ranged from 0.11 to 0.26 which falls with 
in the limit of standard (0.1 to 0.9%). Drug content of tablets was ranged from 
94.87±0.32 to 97.23±0.22, F4 showed maximum drug content. Thickness of tablets 
was uniform and values are ranged from 1.2±0.20 to 1.3±0.14. 
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7.5.1 Buoyancy / Floating Test 
On immersion in 0.1 N hydrochloric acid solution PH (1.2) at 370C, The tablets 
floated, and remained buoyant without disintegration. Table-18 shows the results of 
buoyancy study and shows buoyancy character of prepared tablet. 
The buoyancy lag time for F1-F9 were ranging from 45-90 secs. 
From the results it can be concluded that the batch containing both xanthan 
gum and guar gum showed good buoyancy lag time(BLT) and total floating 
time(TFT). 
Formulation F4 containing xanthan gum and guar gum showed good BLT of 
45 sec, while the formulation containing xanthan gum alone and guar gum alone 
showed highest BLT and TFT of greater than 8 hrs. This may due to the amount of 
polymer and gas generating agent, which were kept constant in the present study. The 
gas generated cannot be entrapped inside the gelatinious layer, and it escapes leading 
to variation in BLT and TFT. 
Table 18: Buoyancy and floating time 
S.No Batch No 
Buoyancy lag time 
(sec) 
Floating duration 
(hrs) 
1 F1 55 >8 hrs 
2 F2 60 >8 hrs 
3 F3 50 >8 hrs 
4 F4 45 >8 hrs 
5 F5 70 >8 hrs 
6 F6 90 >8 hrs 
7 F7 60 >8 hrs 
8 F8 50 >8 hrs 
9 F9 55 >8 hrs 
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Fig No: 9: In vitro buoyancy study of ciprofloxacin hydrochloride floating 
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7.5.2 Swelling Index: 
The percentage swelling obtained from the water uptake studies of the 
formulations is shown in Figure 10-12.  The formulations with xanthan gum and guar 
gum showed the swelling and tablet integrity. The change in sodium bicarbonate 
concentration did not show any effect on swelling of the tablet. Complete swelling 
was achieved at the end of 6 hrs, then diffusion and erosion takes place. The 
formulation containing xanthan gum shows the higher swelling compared to that of 
the formulations containing both xanthan gum and guar gum alone.  The swelling 
index of the tablets increases with an increase in the polymer viscosity grades. 
Table 19: % swelling index of formulated floating tablets 
TIME F1 F2 F3 F4 F5 F6 F7 F8 F9 
1hr 19.54 25.15 18.22 20.1 19.99 19.26 13.05 16.12 11.15 
2hr 32.22 42.1 33.15 28.98 32.14 30.9 18.55 28.76 17.01 
3hr 44.1 56.16 46.1 42.1 45.88 41.1 27.85 43.1 21.85 
4hr 61.12 70.11 63.01 52.9 58.22 53.1 39.75 51.1 31.96 
6hr 69.02 76.12 71.11 63.89 71.03 60.8 46.1 59.65 43.11 
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Fig No.10: Swelling index plot of F1-F3 
 
 
Fig No.11: Swelling index plot of F4-F6 
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Fig No.12: Swelling index plot of F7-F9 
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7.5.3 Invitro drug release study of formulated floating controlled release 
formulations 
Table 20: Invitro drug release study 
TIME CUMULATIVE PERCENTAGE DRUG RELEASE (%) 
 Fl F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 21.01 22.12 26.15 16.08 21.01 8.54 7.15 7.05 9.17 
2 31.22 33.46 36.78 27.11 31.04 16.12 13.32 15.45 19.04 
3 39.04 42.96 45.80 37.65 43.12 25.77 22.78 22.03 28.26 
4 46.05 51.05 52.01 48.76 51.85 34.05 28.04 29.07 34.05 
5 53.04 67.09 63.90 56.04 75.75 46.03 34.08 37.12 45.60 
6 69.09 78.12 78.08 63.06 81.04 50.46 42.21 42.15 51.75 
7 81.98 99.11 92.06 75.05 96.03 55.62 47.67 56.08 60.05 
8 98.32 - 99.34 83.56 99.08 61.26 52.06 66.09 67.07 
10 - - - 90.22 - 71.01 66.45 81.84 72.05 
12 - - - 99.80 - 89.15 78.80 93.71 83.04 
 
Average of n value n=3 
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Fig No.13: Invitro drug release study 
The formulated floating controlled release tablets were then subjected to 
invitro dissolution test for evaluating drug release from the formulation. The invitro 
dissolution test was carried out in 900 ml of 0.1N hydrochloric acid in USP-II paddle 
type apparatus at 50 rpm and 37±0.5oC. The results of dissolution study was depends 
on polymer concentration. Formulation containing xanthan gum alone released fastly 
compared to that guar gum alone due to the less binding nature and controlled release 
property than that of guar gum. Formulation F4 containing xanthan gum (15 mg) and 
guar gum (15 mg) had given drug release 99.80% in 12 hrs. Then the formulations 
containing xanthan gum and guar gum were given better release profiles when 
compared with formulations containing xanthan gum alone and guar gum alone.  
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7.6  KINETIC STUDIES OF FLOATING TABLETS OF CIPROFLOXACIN: 
Table-21:  kinetic study of optimized formulation 
Time 
(hrs) 
Log 
Time 
√Time 
cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
cumulative 
% drug 
remained 
Log 
cumulative 
% drug 
remained 
0 0 0 0 0 100 2.000 
1 0 1.000 16.08 1.206 83.92 1.923 
2 0.312 1.454 27.11 1.433 72.89 1.862 
3 0.624 1.753 37.65 1.575 62.35 1.794 
4 0.715 2.003 48.76 1.688 51.24 1.709 
5 0.798 2.274 56.04 1.748 43.96 1.643 
6 0.945 2.455 63.06 1.799 36.94 1.567 
7 1.090 2.654 75.05 1.875 24.95 1.397 
8 1.175 2.924 83.56 1.921 16.44 1.215 
10 1.345 3.262 90.22 1.955 9.78 0.990 
12 1.398 3.564 99.80 1.999 0.20 -0.698 
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Fig No. 14: Zero order plot 
 
 
Fig No. 15: First order plot 
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Fig No. 16: Higuchi plot 
 
 
Fig No. 17: Korsmeyer peppas plot 
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KINETICS OF DRUG RELEASE 
Table-22: 
Formulation Regression 
coefficient of  
zero order 
Regression 
coefficient of  
first order 
Order of release 
F4 0.963 0.741 Zero order release 
 
Table-23: 
 
Formulation 
Higuchi Model Korsmeyer peppas model 𝐑𝟐 𝐑𝟐 
F4 0.974 0.675 
 
In order to determine the mechanism of drug release form the formulations, 
the Invitro dissolution data was fitted to zero order, first order, higuchi plot and 
korsmeyer-peppas plot was drawn and interpretation of release exponent value (n) 
was calculated and results are shown in tables 22-23; figs 14-17. The results of R2 for 
zero and first order were obtained as 0.963, 0.741. Based on that we will confirm the 
optimized formulation followed zero order release. 
The drug release was diffusion controlled as the plot of optimized formulation 
F4 was found 0.974 as regression coefficient in higuchi plot. From korsmeyer peppas 
plot the release exponent value n was found as 0.675 and it was confirmed as the 
release of drug from the formulation was founded as anomalous non-fickian transport 
of diffusion. 
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7.7 STABILITY STUDIES: 
 The optimized formulation was subjected to stability studies at 40oC ± 2oC / 
75% RH ± 5% for 3 months. 
The product was evaluated for following parameters: 
 Weight variation 
 Hardness 
 Friability 
 Drug content 
 Dissolution analysis 
1) Storage condition at 40°C±2°C/75%RH±5%: 
Table-24: 
TEST 0 days 30 days 60 days 90 days 
Weight 
variation 
99±0.87 99±0.55 98±0.84 99±0.76 
Hardness 4.5 4.4 4.4 4.3 
Friability 0.68 0.69 0.69 0.70 
Drug content 99.83±0.04 99.59±0.07 99.39±0.07 99.28±0.06 
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7.7.1 Dissolution data of percent cumulative drug release for formulation F4 
Table-25: Dissolution data of stability formulation F4 
Time (hrs) 0 days 30 days 60 days 90 days 
0 0 0 0 0 
1 16.15 16.10 15.57 15.65 
2 26.75 25.37 25.12 24.92 
3 37.80 36.66 36.70 36.48 
4 49.12 48.48 46.54 43.82 
5 56.15 54.76 52.62 51.55 
6 62.65 62.32 60.85 60.12 
7 75.16 74.35 73.45 72.58 
8 83.60 82.76 82.32 82.02 
10 91.15 91.72 91.32 91.54 
12 99.75 99.60 99.44 99.34 
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Fig. No. 18:  Dissolution data of stability for formulation F4 
The stability studies for optimized formulation F4 was carried out based 
accelerated stability conditions & study of various parameters carried out at 0, 30, 60, 
90 days of intervals and the results found satisfactorily and that reveals that the 
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8. SUMMARY AND CONCLUSION 
 
The main objective of the present study was to develop floating formulation 
containing 250 mg of ciprofloxacin hydrochloride for twice therapy using natural 
polymers like xanthan gum and guar gum. GRDDS improved the bioavailability and 
therapeutic efficiency of drug. 
  
In the preformulation, FTIR study was carried out for pure drug (ciprofloxacin 
hydrochloride), ciprofloxacin hydrochloride and excipients. It has not shown any 
interaction. Hence drugs were found to be compatible with excipients. 
 
The formulations were prepared by direct compression method. The angle of 
repose values for formulations range from 25.04±0.02 to27.10 ±0.06. Bulk and tapped 
densities were used for the measurement of compressibility index. The bulk and 
tapped values for formulations range from 0.25±0.05 to 0.33±0.04 and 0.32±0.04 to 
0.38±0.02 respectively the car’s index and harusner’s ratio values for formulations 
range from 1.05±0.03 to 1.37±0.05 respectively. Thus all formulations exhibited good 
flow characteristics. 
 
The prepared floating tablets were evaluated for various parameters like 
thickness, weight variation, hardness, friability and drug content uniformity. The 
thickness of tablets in all formulations were ranged from 3.2±0.16 to 3.3±0.14. The 
weight variation of tablets in all formulations were ranged from 318±1.6 to 320±6.1. 
The hardness and friability of all the formulations F1-F9 was found to be 4.0±0.6 to 
4.1±0.4 and 0.11 to 0.26 respectively. Drug content of all the formulations were 
ranging from 95.14±0.23 to 97.23±0.22. The buoyancy lag time of all the 
formulations were ranging from 45sec to 90sec. 
 
Compared to all formulations F4 showed the best buoyancy lag time, the 
buoyancy lag time for F4 was found to be 45sec. Total floating time of all 
formulations was found to be >8 hrs. The formulation containing xanthan gum shows 
the higher swelling compared to that of the formulations containing both xanthan and 
guar gum alone. 
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The prepared tablets were then subjected to dissolution test for evaluating the 
invitro drug release. The dissolution studies were carried out in 0.1N hydrochloric 
acid in USP-32 appatarus at 37±0.5°C. The results of the dissolution studies indicated 
that the polymer concentration was having a substantial effect on the drug release 
from the tablets. Formulation F4 gave better controlled drug release and floating 
properties in comparision to the other formulations. This formulation took 45sec to 
become buoyant. 
 
The kinetic study was carried out for F4 formulation which showed that the 
drug release followed zero order kinetics followed by non-fickian diffusion. 
 
The stability studies were carried out for F4 formulation at 45°C 175% RH for 
3months. Data revelead that there was no considerable difference. 
 
From the above study, concluded that F4 was the optimized formulation which 
has shown better buoyancy time 45sec and drug release 99.80% in 8hrs. However, 
further invivo studies can be carried out to support the results. 
 
The overall results explained that the tablets prepared by combination of 
xanthan gum and guar gum could be more effective on floating tablets and has shown 
more sustained effect than floating tablets containing natural polymer alone. 
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